CMRO Current Medical Research & Opinion Sample - C Volume 25

XML Template (2009) [7.9.2009–9:27am] [1–14]
{TANDF_FPP}CMO/CMO_A_370737(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
Acknowledgments
12. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing
metformin therapy in patients with type 2 diabetes. Curr Med Res Opin
Declaration of interest
2008;24:537-50
ThestudywasfundedbyMerck&Co.,Inc.,WhitehouseStation,
13. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when
added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes
NJ,USA.Alistofstudyinvestigatorswaspreviouslypublishedin
Obes Metab 2008;10:959-69
Goldstein et al.
15
.
14. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of
All authors are employees of Merck & Co., Inc. and may own
sitagliptin in patients with type 2 diabetes: A pooled analysis. BMC Endocr
stock or have stock options in the company.
Disord 2008;8:14
15. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination
therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on
glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:
References
1979-87
16. Herman GA, Stein PP, Thornberry NA, et al. Dipeptidyl peptidase-4 inhibitors
1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of
for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther
rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;
2007;81:761-7
355:2427-43
17. Drucker DJ, Nauck MA. GLP-1R agonists (incretin mimetics) and DPP-4
2. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea,
inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet
metformin, or insulin in patients with type 2 diabetes mellitus: progressive
2006;368:1696-705
requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes
18. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of
Study (UKPDS) Group. JAMA 1999;281:2005-12
sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose
3. Canadian Diabetes Association Clinical Practice Guidelines Expert
levels following an oral glucose tolerance test in patients with type 2 diabetes.
Committee. Pharmacologic treatment of Diabetes. Can J Diabetes 2008;
J Clin Endocrinol Metab 2006;91:4612-19
32(Suppl 1):S53-S61
19. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl
4. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-
peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in
4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type
patients with type 2 diabetes inadequately controlled on metformin alone.
2 diabetes. Diabetes Care 2006;29:2632-7
Diabetes Care 2006;29:2638-43
5. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4
20. Xu L, Dalla Man C, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl
inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes:
Diabetologia 2006;49:2564-71 a model-based approach. Diabetes Obes Metab 2008 May;12; doi: 10.1111/
6. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl
j.1463-1326.2008.00887.x
peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus 21. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl
inadequately controlled on glimepiride alone or on glimepiride and metformin. peptidase-4 inhibitor, to metformin on 24-hour glycemic control and
Diabetes Obes Metab 2007 26;9:733-45 C12-cell function in patients with type 2 diabetes. Diabetes Obes Metab
7. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl 2007;9:186-93
peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. 22. Scarpello JH, Howlett HC, Metformin therapy and clinical uses. Diab Vasc Dis
Curr Med Res Opin 2007;23:1329-39 Res 2008;5:157-67
8. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin mono- 23. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-
therapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
2008;79:291-8 Diabetes Care 2001;24:489-94
9. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl 24. Migoya EM, Miller J, Larson P, et al. Sitagliptin, a selective DPP-4 inhibitor,
peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in and metformin have complementary effects to increase active GLP-1 con-
patients with type 2 diabetes inadequately controlled on metformin alone: a centrations (abstract). Diabetes 2007;56(Suppl 1):A74
randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 25. Bloomgarden ZT, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces
2007;9:194-205 apparent oral agent glucose-lowering efficacy: a meta-regression analysis.
10. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl Diabetes Care 2006;29:2137-9
peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in 26. Basu A, Shah P, Nielsen M, et al. Effects of type 2 diabetes on the regulation of
patients with type 2 diabetes: A 24-week, multicenter, randomized, hepatic glucose metabolism. J Investig Med 2004;52:366-74
double-blind, placebo-controlled parallel group study. Clin Ther 2006; 27. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction
28:1556-68 and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;
11. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl 32(Suppl 3):35-45
peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients 28. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific
with type 2 diabetes. Int J Clin Pract 2007;61:171-80 review. JAMA 2002;287:360-72
14
54-week efficacy and safety of sitagliptin/metformin Williams-Herman et al. www.cmrojournal.com
!
2009 Informa UK Ltd
Page 1 | Page 2 | Page 3 | Page 4 | Page 5 | Page 6 | Page 7 | Page 8 | Page 9 | Page 10 | Page 11 | Page 12 | Page 13 | Page 14 | Page 15 | Page 16 | Page 17 | Page 18 | Page 19 | Page 20 | Page 21 | Page 22 | Page 23 | Page 24 | Page 25 | Page 26 | Page 27 | Page 28 | Page 29 | Page 30 | Page 31 | Page 32 | Page 33 | Page 34